Literature DB >> 18533284

Distribution of IgM and IgG antibodies to oxidized LDL in immune complexes isolated from patients with type 1 diabetes and its relationship with nephropathy.

Gabriel Virella1, Rickey E Carter, Antonio Saad, Edward G Crosswell, B Andrew Game, Maria F Lopes-Virella.   

Abstract

Modified lipoproteins are immunogenic and play a key pathogenic role in vascular disease. Antibodies to oxidized LDL (oxLDL) are mostly of the pro-inflammatory IgG1 and IgG3 isotypes. We measured IgG and IgM oxLDL antibodies in immune complexes (IC) isolated from 36 patients with type 1 diabetes using a nested case control design. IgG antibodies predominated over IgM antibodies by an 8:1 ratio. IgG antibody concentrations were higher in the nephropathy cases compared to controls (p = 0.09), but no significant difference was observed because of two patients included in the study who had end-stage renal disease (creatinine > 5 mg/dL and glomerular filtration rate (GFR) less than 17 mL/min). After eliminating these patients from the analysis, significant positive associations of IgG antibody concentration with serum creatinine and albumin excretion rate were observed. Similarly, a negative correlation with estimated glomerular filtration rate was observed in this subsample of 34 patients. Differences in IgM antibody concentrations by nephropathy classification were not supported by the data. In conclusion, the predominance of pro-inflammatory IgG oxLDL antibodies is associated with existence of diabetic nephropathy, and a protective role of IgM antibodies could not be demonstrated.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18533284      PMCID: PMC2601558          DOI: 10.1016/j.clim.2008.02.005

Source DB:  PubMed          Journal:  Clin Immunol        ISSN: 1521-6616            Impact factor:   3.969


  49 in total

1.  Antibodies to oxidized LDL in relation to intima-media thickness in carotid and femoral arteries in 58-year-old subjectively clinically healthy men.

Authors:  J Hulthe; L Bokemark; B Fagerberg
Journal:  Arterioscler Thromb Vasc Biol       Date:  2001-01       Impact factor: 8.311

2.  The preparation of copper-oxidized LDL for the measurement of oxidized LDL antibodies by EIA.

Authors:  M F Lopes-Virella; S Koskinen; M Mironova; D Horne; R Klein; C Chassereau; C Enockson; G Virella
Journal:  Atherosclerosis       Date:  2000-09       Impact factor: 5.162

Review 3.  Innate and acquired immunity in atherogenesis.

Authors:  Christoph J Binder; Mi-Kyung Chang; Peter X Shaw; Yury I Miller; Karsten Hartvigsen; Asheesh Dewan; Joseph L Witztum
Journal:  Nat Med       Date:  2002-11       Impact factor: 53.440

4.  Autoantibodies against oxidized low-density lipoprotein and cardiolipin in patients with coronary heart disease.

Authors:  A T Erkkilä; O Närvänen; S Lehto; M I Uusitupa; S Ylä-Herttuala
Journal:  Arterioscler Thromb Vasc Biol       Date:  2000-01       Impact factor: 8.311

5.  Proatherogenic and proinflammatory properties of immune complexes prepared with purified human oxLDL antibodies and human oxLDL.

Authors:  G Virella; D Atchley; Sinikka Koskinen; D Zheng; Maria F Lopes-Virella
Journal:  Clin Immunol       Date:  2002-10       Impact factor: 3.969

6.  Antibodies to oxidized LDL in relation to carotid atherosclerosis, cell adhesion molecules, and phospholipase A(2).

Authors:  J Hulthe; O Wiklund; E Hurt-Camejo; G Bondjers
Journal:  Arterioscler Thromb Vasc Biol       Date:  2001-02       Impact factor: 8.311

7.  Immunochemical characterization of purified human oxidized low-density lipoprotein antibodies.

Authors:  G Virella; S Koskinen; G Krings; J M Onorato; S R Thorpe; M Lopes-Virella
Journal:  Clin Immunol       Date:  2000-05       Impact factor: 3.969

8.  Oxidized LDL-anti-oxidized LDL immune complexes and diabetic nephropathy.

Authors:  D H Atchley; M F Lopes-Virella; D Zheng; D Kenny; G Virella
Journal:  Diabetologia       Date:  2002-10-12       Impact factor: 10.122

Review 9.  Humoral immune responses in uremia and the role of IL-10.

Authors:  Matthias Girndt
Journal:  Blood Purif       Date:  2002       Impact factor: 2.614

10.  Autoimmune response to advanced glycosylation end-products of human LDL.

Authors:  Gabriel Virella; Suzanne R Thorpe; Nathan L Alderson; Elias M Stephan; Daniel Atchley; Francesco Wagner; Maria F Lopes-Virella
Journal:  J Lipid Res       Date:  2002-12-01       Impact factor: 5.922

View more
  19 in total

Review 1.  Atherogenesis and the humoral immune response to modified lipoproteins.

Authors:  Gabriel Virella; Maria F Lopes-Virella
Journal:  Atherosclerosis       Date:  2008-04-12       Impact factor: 5.162

Review 2.  Role of the Immune System in Diabetic Kidney Disease.

Authors:  Fionnuala B Hickey; Finian Martin
Journal:  Curr Diab Rep       Date:  2018-03-12       Impact factor: 4.810

3.  Deficiency of a transcriptional regulator, inhibitor of differentiation 3, induces glomerulonephritis in apolipoprotein E-deficient mice: a model linking hyperlipidemia and renal disease.

Authors:  Harini Bagavant; Yogesh Scindia; Dominika Nackiewicz; Seshagiri Rao Nandula; Amanda Doran; Alexis Cutchins; Stephanie Oldham; Umesh Deshmukh; Coleen McNamara
Journal:  Am J Pathol       Date:  2011-06-14       Impact factor: 4.307

4.  BTBR ob/ob mice as a novel diabetic neuropathy model: Neurological characterization and gene expression analyses.

Authors:  Phillipe D O'Brien; Junguk Hur; John M Hayes; Carey Backus; Stacey A Sakowski; Eva L Feldman
Journal:  Neurobiol Dis       Date:  2014-10-30       Impact factor: 5.996

5.  The association between serum levels of oxLDL-lgG and oxLDL-lgM autoantibody with adult acute myeloblastic leukaemia.

Authors:  Hao Li; Yu Tao Diao; Hui Qing Li; Qing Ma; Jia Cui; Ying Zhi Zhou; Dong Li
Journal:  Lipids Health Dis       Date:  2010-01-31       Impact factor: 3.876

6.  The levels of MDA-LDL in circulating immune complexes predict myocardial infarction in the VADT study.

Authors:  Maria F Lopes-Virella; Kelly J Hunt; Nathaniel L Baker; Gabriel Virella; Thomas Moritz
Journal:  Atherosclerosis       Date:  2012-08-21       Impact factor: 5.162

Review 7.  Clinical significance of the humoral immune response to modified LDL.

Authors:  Maria F Lopes-Virella; Gabriel Virella
Journal:  Clin Immunol       Date:  2009-05-08       Impact factor: 3.969

8.  ASSOCIATIONS BETWEEN ACCELERATED ATHEROSCLEROSIS, OXIDIZED LDL IMMUNE COMPLEXES, AND IN VITRO ENDOTHELIAL DYSFUNCTION IN SYSTEMIC LUPUS ERYTHEMATOSUS.

Authors:  Jim C Oates; Viswanathan Ramakrishnan; Paul J Nietert; J David Spence; Thomas W Fleury; Margaret Markiewicz; Dayvia L Russell; Maria F Lopes-Virella
Journal:  Trans Am Clin Climatol Assoc       Date:  2020

9.  Oxidized LDL and AGE-LDL in circulating immune complexes strongly predict progression of carotid artery IMT in type 1 diabetes.

Authors:  Kelly J Hunt; Nathaniel Baker; Patricia Cleary; Jye-Yu Backlund; Timothy Lyons; Alicia Jenkins; Gabriel Virella; Maria F Lopes-Virella
Journal:  Atherosclerosis       Date:  2013-10-11       Impact factor: 5.162

10.  Association of serum levels of lipid and its novel constituents with the different stages of esophageal carcinoma.

Authors:  Yutao Diao; Hao Li; Huiqing Li; Yingzhi Zhou; Qing Ma; Yan Wang; Dong Li
Journal:  Lipids Health Dis       Date:  2009-10-29       Impact factor: 3.876

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.